1. FDA review of Arcoxia and Prexige shows potential CV risk

   News item 22 January 2013 Pages: 2 - 2

2. UK MHRA to review prohibition of Kavain, invites submissions

   News item 22 January 2013 Pages: 2 - 2

3. Canadian Ezetrol label change reflects adverse event reports

   News item 22 January 2013 Pages: 3 - 3

4. Capadex and Paradex use in New Zealand to be reviewed

   Media release 22 January 2013 Pages: 3 - 3

5. Safety information updated on Canadian Humira label

   News item 22 January 2013 Pages: 3 - 3

6. Xigris may increase mortality rate in surgical patients

   News item 22 January 2013 Pages: 3 - 3

7. Apotex updates Canadian Apo-Mefloquine patient leaflet

   News item 22 January 2013 Pages: 4 - 4

8. Bisphosphonate-associated jaw necrosis in Singapore and Australia

   News item 22 January 2013 Pages: 4 - 4

9. Isotretinoin: ADRAC reiterates absolute contraindication during pregnancy

   News item 22 January 2013 Pages: 4 - 4

10. Pergolide-associated valvular heart disease in Singapore

    News item 22 January 2013 Pages: 4 - 4

11. Statins now pregnancy Category D in Australia

    News item 22 January 2013 Pages: 4 - 4

12. UK CSM advises of liver disorders reported with Strattera

    News item 22 January 2013 Pages: 4 - 4

13. ADR database highlights SSRI-associated neonatal withdrawal

    Clinical study 22 January 2013 Pages: 5 - 5

14. Further evidence rofecoxib increases MI risk in elderly

    Incidence study 22 January 2013 Pages: 5 - 5

15. Genetic + immune factors increase nevirapine hypersensitivity risk

    Clinical study 22 January 2013 Pages: 5 - 5

16. Rofecoxib, but not celecoxib or naproxen, increases BP

    Clinical study 22 January 2013 Pages: 5 - 5

17. Alendronic acid

    Case reports 22 January 2013 Pages: 6 - 6

18. Antiretrovirals

    Case report 22 January 2013 Pages: 6 - 6

19. Atorvastatin interaction

    Case report 22 January 2013 Pages: 7 - 7

20. Fluoxetine

    Case reports 22 January 2013 Pages: 7 - 7

21. Hydrochlorothiazide

    Case report 22 January 2013 Pages: 7 - 7

22. Immunoglobulins

    Case report 22 January 2013 Pages: 7 - 8

23. Infliximab

    Case report 22 January 2013 Pages: 8 - 8

24. Infliximab

    Case report 22 January 2013 Pages: 8 - 8

25. Insulin

    Case report 22 January 2013 Pages: 8 - 8

26. Interferon alfacon-1

    Case report 22 January 2013 Pages: 9 - 9

27. Levothyroxine sodium

    Case report 22 January 2013 Pages: 9 - 9

28. Mercaptopurine

    Case report 22 January 2013 Pages: 9 - 10

29. Mitomycin

    Case report 22 January 2013 Pages: 10 - 10

30. Olanzapine

    Case report 22 January 2013 Pages: 10 - 10

31. Oxaliplatin

    Case report 22 January 2013 Pages: 10 - 10

32. Paroxetine

    Case report 22 January 2013 Pages: 11 - 11

33. Peginterferon-α-2b/ribavirin

    Case report 22 January 2013 Pages: 11 - 11

34. Pramipexole

    Case report 22 January 2013 Pages: 11 - 11

35. Resorcinol

    Case report 22 January 2013 Pages: 12 - 12

36. Rofecoxib

    Case report 22 January 2013 Pages: 12 - 12

37. Ropivacaine

    Case report 22 January 2013 Pages: 12 - 12

38. Sodium cromoglicate

    Case report 22 January 2013 Pages: 13 - 13

39. Tacrolimus withdrawal

    Case report 22 January 2013 Pages: 13 - 13

40. Tamsulosin

    Case report 22 January 2013 Pages: 13 - 13

41. Thiethylperazine

    Case report 22 January 2013 Pages: 13 - 14

42. Tramadol

    Case report 22 January 2013 Pages: 14 - 14

43. Valaciclovir overdose

    Case report 22 January 2013 Pages: 14 - 14

44. Valdecoxib

    Case reports 22 January 2013 Pages: 14 - 14

45. Vardenafil

    Case report 22 January 2013 Pages: 15 - 15